

**A Phase 1b Clinical Trial to Determine the Safety, Tolerability and
Immunogenicity of Simian Adenovirus and Poxvirus vectored vaccines against
Mycobacterium avium complex subspecies in Patients with Active Crohn's
Disease**

Appendix 1 - Supplementary Data

Analysis of primary endpoints

Safety

Total number of solicited AEs was 196 in all 28 (100%) participants. Of all solicited AEs, 149/196 (76.0%, 95% CI 69.6%-81.5%) were graded as mild and 45/196 (23.0%, 95% CI 17.2%-28.8%) were graded as moderate. One AE was graded as severe (Group 1, Low dose ChAdOx2 HAV). Most of solicited AEs completely resolved within 7 days (187/196, 95.4%) and the majority (111/196, 56.6%) had their onset within the first 72 h post vaccination (64/196, 32.6% at D0, 27/196, 13.8% at D1 and 20/196, 10.2% at D2). In Group 5, pain at injection site was the most common local adverse event reported by 6 participants when injecting ChAdOx2 HAV and 8 when injecting MVA HAV. Total solicited adverse events in group 5 is summarized in Table 1.

Systemic/Local	Adverse Event	ChAdOx2 (n=10) 5x10 ¹⁰ vp	MVA HAV (n=9) 2x10 ⁸ pfu
Local	Pain	6	8
	Warmth	1	1
Systemic	Arthralgia	2	2
	Fatigue	6	6
	Feverishness	2	3
	Headache	4	7
	Malaise	3	3
	Myalgia	4	5
	Nausea	2	0

**A Phase 1b Clinical Trial to Determine the Safety, Tolerability and
Immunogenicity of Simian Adenovirus and Poxvirus vectored vaccines against
Mycobacterium avium complex subspecies in Patients with Active Crohn's
Disease**

Table S1: Total solicited adverse events in Group 5

A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium* *complex* subspecies in Patients with Active Crohn's Disease

Solicited AEs in 7 days post vaccination:

A total of 164 local and systemic solicited AEs were reported by 28/28 (100%) participants within 7 days post vaccination. The vast majority of solicited AEs were mild (129/165; 78.2%, 95% CI 71.3%–83.8%) or moderate (35/165; 21.2%, 95% CI 15.7%–28.1%). One solicited AE was graded as severe and lasted for 1 day (Group 1, Low dose ChAdOx2 HAV). Percentages of local and systemic solicited AEs reported during the first 7 days are summarised in Supplementary Data 2 Figure 1.




Figure S1: Percentage of participants reporting solicited local and systemic adverse events within 7 days of vaccination. Yellow: mild, Orange: Moderate, Red: Severe.

**A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of
Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium*
complex subspecies in Patients with Active Crohn's Disease**

	Total enrolled	Number experiencing Grade 3 SAR lasting more than 48 hours	Proportion experiencing Grade 3 SAR lasting more than 48 hours	Number of expected local reactogenicity signs and symptoms for 7 days following the vaccination	Number of expected systemic reactogenicity signs and symptoms for 7 days following the vaccination	Number of unexpected adverse events for 28 days following the vaccination	Number of serious adverse events during the whole study duration
Group 1	6	1	0.17	9	37	2	0
Group 2	6	0	0	4	23	5	0
Group 3	3	0	0	4	12	1	0
Group 4	3	0	0	9	30	0	1
Group 5	10	0	0	17	76	3	1

Table S2: Summary of adverse events by Group

**A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of
Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium*
complex subspecies in Patients with Active Crohn's Disease**

Group	Adverse Event	Start Date	End date	Duration (days)
1	Severe Migraine Attack	14/11/2021	17/11/2021	4
	Flare up of Neck pain	22/11/2021	22/11/2021	1
	Feverish	22/11/2021	23/11/2021	2
	Indigestion	30/11/2021	01/12/2021	2
	Heartburn	30/11/2021	01/12/2021	2
	Insomnia	30/11/2021	01/12/2021	2
2	Breathless	17/12/2021	18/12/2021	2
5	Perianal abscess	01/07/2022	05/07/2022	5

Table S3: Grade 3 Adverse Events

A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium* complex subspecies in Patients with Active Crohn's Disease

The median and range of values of safety laboratory measures are plotted by group at baseline (vaccination visit) and 7 days post vaccination.




Figure S2: Laboratory values at baseline (Vaccination visit)

A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium* complex subspecies in Patients with Active Crohn's Disease




Figure S3: Laboratory values at 7 days post vaccination

**A Phase 1b Clinical Trial to Determine the Safety, Tolerability and Immunogenicity of
Simian Adenovirus and Poxvirus vectored vaccines against *Mycobacterium avium*
complex subspecies in Patients with Active Crohn's Disease**

Crohn's disease activity index (CDAI) during study and Simple Endoscopic Score for Crohn's Disease (SES-CD)

Group	Participant	CDAI			SES-CD	
		Screening	Day 56	Day 112	Screening	Day 112
1	1	74	40	NA	NA	NA
	4	189	276	NA	NA	NA
	7	71	58	NA	NA	NA
	8	206	140	NA	NA	NA
	11	333	159	NA	NA	NA
	12	168	2	NA	NA	NA
2	6	231	86	NA	NA	NA
	9	178	3	NA	NA	NA
	10	243	42	NA	NA	NA
	15	243	53	NA	NA	NA
	16	180	56	NA	NA	NA
	17	170	14	NA	NA	NA
3	5	227	213	NA	NA	NA
	18	249	263	NA	NA	NA
	20	159	56	NA	NA	NA
4	35	183	167	NA	NA	NA
	34	262	58	NA	NA	NA
	33	182	97	NA	NA	NA
5	13	204	96	18	3	3
	19	99	35	76	17	6
	22	246	111	171	26	14
	23	154	51	66	8	6
	24	263	83	66	6	5
	28	286	68	142	11	5
	29	189	69	20	8	3
	30	176	66	27	7	4
	31	294	165	158	11	3

Table S4: Crohn's disease activity index (CDAI) during study and Simple Endoscopic Score for Crohn's Disease (SES-CD)